Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 93

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Lexicon Pharmaceuticals Inc.

Study on Long-Term Safety of Tegoprubart and Tacrolimus for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tacrolimus
  • Sponsor:Eledon Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study on the Effectiveness of IC0624 for Patients with Mild to Moderate Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Sodium bituminosulfonate dry substance
  • Sponsor:Ichthyol-Gesellschaft Cordes Hermanni & Co. GmbH & Co. KG

Migraine

Not recruiting

Study on Atogepant for Preventing Menstrual Migraine in Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1607
  • Sponsor:BioInvent International AB

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Hidradenitis+1

Not recruiting

Study on the Safety of INF904 for Patients with Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INF904
  • Sponsor:InflaRx GmbH

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Psoriasis

Not recruiting

Study on the Effects of Deucravacitinib for Patients with Moderate to Severe Plaque Psoriasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Urticaria chronic

Not recruiting

Study on Long-Term Safety of Briquilimab for Patients with Chronic Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.